Key Takeaways
• Nausea, diarrhea, and vomiting are the most common Wegovy side effects, affecting up to 44% of users at the full 2.4 mg dose. Most improve within 4 to 8 weeks.
• Hair loss (telogen effluvium) was reported in 3% of Wegovy trial participants versus 1% on placebo. It is linked to rapid weight loss, not the drug itself.
• The FDA thyroid warning applies to a rare cancer type (MTC). Large human studies have not confirmed a significant risk in the general population.
Wegovy (semaglutide 2.4 mg) is now among the most prescribed weight-management medications globally, and conversations about it are picking up in India’s urban health circles. If you are new to the brand, our primer on what is Wegovy explains the basics before you dig into the safety detail below.
Before you consider it, or if you have already started, you deserve a clear, clinically grounded picture of what its side effects actually look like.
This guide walks through seven categories of side effects, from the common to the serious, what the evidence says, and how to manage each.
1. Nausea, Vomiting, and Diarrhea: The Side Effects Most People Talk About
Gastrointestinal (GI) symptoms are, without question, the most common Wegovy side effects. In the pivotal STEP-1 trial published in the New England Journal of Medicine (2021), nausea affected approximately 44% of participants at the full 2.4 mg dose.
Diarrhea was reported in roughly 30% and vomiting in around 24%.
These numbers can sound alarming. The crucial context: the dose is titrated slowly over five months, starting at 0.25 mg per week before reaching the full 2.4 mg.
That gradual increase is specifically designed to give your gut time to adjust, and for most people, symptoms improve significantly within four to eight weeks of reaching a stable dose.
The mechanism is straightforward. Semaglutide slows gastric emptying, the rate at which food leaves your stomach.
This is intentional: it extends satiety. The same mechanism, however, means the stomach may feel unsettled while digesting, particularly after larger meals or high-fat foods. A 2023 JAMA review by Sodhi et al. confirmed that gut symptoms remain the most commonly reported adverse events across GLP-1 medications. For a deeper dive specifically into constipation on Wegovy, our dedicated guide covers the gut-slowdown mechanism and remedies in detail.
GI Side Effects at a Glance (STEP trials, NEJM 2021)
| Side Effect | Wegovy 2.4 mg | Placebo | Typical Duration |
| Nausea | ~44% | ~16% | 4-8 weeks per dose step |
| Diarrhea | ~30% | ~16% | Improves over weeks |
| Vomiting | ~24% | ~6% | Typically brief episodes |
| Constipation | ~24% | ~11% | May persist longer |
| Abdominal pain | ~20% | ~13% | Variable |
Sources: Wilding et al., NEJM 2021 (STEP-1) | Novo Nordisk FDA Prescribing Information, 2025
How to manage GI symptoms on Wegovy
- Eat smaller portions at each meal. Semaglutide amplifies satiety signals, so large meals increase the chance of nausea.
- Avoid high-fat, fried, or heavily spiced foods during the first weeks at each new dose. These take longer to digest.
- Stay hydrated, especially if vomiting or diarrhea occur. Small, frequent sips work better than large gulps.
- Inject Wegovy at a consistent time each week. If nausea clusters in the 48 hours after your injection, schedule the shot for a day when you have a lighter schedule.
- If symptoms do not improve after four to six weeks at a dose, talk to your prescribing doctor. A temporary dose reduction is clinically reasonable and does not mean stopping treatment.
Only about 3% of adults in clinical trials discontinued Wegovy specifically because of gastrointestinal side effects, per the FDA prescribing information. That number provides a useful perspective: most people tolerate them.
2. Does Wegovy Cause Hair Loss? What the Evidence Really Says
Hair loss is a frequently searched Wegovy concern, and the worry is understandable. Alopecia was reported in 3% of adults in the Wegovy clinical trials versus 1% in the placebo group, according to the FDA prescribing information. For a semaglutide-specific deep dive into hair loss on Wegovy, see our full breakdown of the clinical data.
The relative difference is real. The cause, however, is more nuanced than simply blaming the drug.
Telogen effluvium: the mechanism behind the shedding
The leading explanation in published research is telogen effluvium, a form of temporary, diffuse hair shedding triggered by physiological stress on the body.
Any significant, rapid weight loss, whether from bariatric surgery, crash dieting, or a GLP-1 medication like semaglutide, can push hair follicles into the resting (telogen) phase prematurely.
The result is increased shedding, typically appearing two to four months after the physiological stress begins.
This pattern was confirmed in the Wegovy trial data itself. Among participants who lost more than 20% of their body weight, alopecia was reported in 5.3%. Among those who lost less than 20%, the rate was 2.5%. The greater the weight loss, the higher the hair loss signal, pointing toward the weight loss as the driver, not semaglutide itself.
What peer-reviewed studies show
A 2025 retrospective cohort study published in the Journal of the American Academy of Dermatology (Burke et al.) found that among semaglutide users, women had a statistically higher risk of hair loss (hazard ratio: 2.08 [95% CI: 1.17 to 3.72]) compared to those on bupropion-naltrexone, another weight-loss agent producing less rapid weight reduction.
A 2024 scoping review published in the Journal of the American Academy of Dermatology (Tran et al.) identified dermatologic findings associated with semaglutide use, with alopecia featuring prominently.
A separate 2025 analysis in the Journal of Cosmetic Dermatology (Haykal) noted that rapid weight loss leads to nutritional deficiencies, particularly of iron, zinc, vitamin D, and biotin, which may worsen telogen effluvium. Adequate protein intake and micronutrient monitoring may reduce severity.
A 2025 systematic review in PMC examining GLP-1 receptor agonist-associated hair loss concluded that semaglutide shows a disproportionate signal for alopecia in pharmacovigilance databases, but that the magnitude of weight loss directly influences severity.
The encouraging clinical picture: telogen effluvium is typically self-limiting. Hair shedding usually peaks within the first few months and reverses as weight stabilises. It rarely causes permanent hair loss.
Practical steps if you notice hair thinning
- Ask your doctor to check ferritin, vitamin D, zinc, and serum protein levels. Correcting deficiencies can reduce shedding.
- Ensure adequate dietary protein intake. Current guidance suggests at least 1.2 g of protein per kg of body weight during active weight loss.
- Avoid additional hair stressors during this period: excessive heat styling, tight hairstyles, and harsh chemical treatments.
- If shedding is severe or does not improve within six months of weight stabilisation, consult a dermatologist for a formal evaluation.
3. Why Does Wegovy Make You Feel Tired? Breaking Down Wegovy-Related Fatigue
Fatigue is listed among the adverse reactions occurring in 5% or more of Wegovy users in the FDA prescribing information, placing it in the same tier as nausea and headache. It is real, and it is worth understanding. For a semaglutide-specific deep dive on fatigue on Wegovy, our companion guide explains how to recover energy day-by-day.
Several mechanisms may contribute. First, a significant caloric reduction from appetite suppression reduces total energy intake. When the body receives fewer calories, energy output can feel slower.
Second, dehydration from nausea or vomiting reduces blood volume and can cause lethargy. Third, disrupted sleep from GI discomfort in the first weeks of treatment can compound tiredness during the day.
In the STEP-1 trial (NEJM 2021), fatigue typically clustered in the 48 to 72 hours immediately after each injection, corresponding to the peak serum concentration of semaglutide.
As the body adjusts to each dose level, injection-day fatigue tends to diminish. The STEP-5 two-year trial (Nature Medicine 2022) found no new fatigue-related risks emerging beyond the first year of treatment.
When fatigue warrants medical attention
- If fatigue is accompanied by significantly reduced urination, extreme weakness, or swelling in the legs, contact your doctor promptly. These can signal dehydration-related kidney stress.
- If fatigue is constant and does not improve after the first few weeks at a dose, ask your prescribing doctor to check thyroid function, haemoglobin (to rule out anaemia from dietary restriction), and electrolytes.
- Dose-day fatigue that is mild and short-lived does not typically require any intervention. Rest when needed and plan lighter activities for the day after your injection.
4. The Thyroid Cancer Warning: What It Actually Means (and Does Not Mean)
Wegovy carries an FDA boxed warning, the most serious warning type, about the risk of thyroid C-cell tumours, including medullary thyroid carcinoma (MTC).
This warning is prominently placed and frequently misread. Here is precisely what the science says.
Where the warning comes from
In animal studies (mice and rats given semaglutide at clinically relevant doses), there was a dose-dependent, duration-dependent increase in thyroid C-cell tumours.
The FDA prescribing information states clearly: “It is unknown whether Wegovy causes thyroid C-cell tumours, including MTC, in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumours has not been determined.”
What large human studies show
A 2024 Scandinavian cohort study published in the BMJ (Pasternak et al.) examined GLP-1 receptor agonist use and thyroid cancer risk across a large population. The researchers did not find a significant increase in common thyroid cancer types.
A 2024 systematic literature review published in the International Journal of Molecular Sciences analysed ten randomised controlled trials involving 14,550 participants.
Thyroid cancer incidence was notably low across all studies, with isolated cases constituting less than 1% of respective study groups. The authors concluded: no significant risk was established with the available evidence.
A 2025 multinational cohort study in Thyroid (Baxter et al.) further supported the absence of a meaningful thyroid cancer signal in human populations.
Who is genuinely contraindicated
Two absolute contraindications apply here, per the FDA prescribing information:
- Personal or family history of medullary thyroid carcinoma (MTC).
- Diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Outside these two groups, the current evidence does not support widespread thyroid cancer risk in humans.
If you develop a lump or swelling in the neck, persistent hoarseness, difficulty swallowing, or shortness of breath while on Wegovy, contact your doctor immediately.
5. Pancreatitis and Wegovy: A Rare but Serious Risk You Should Understand
Acute pancreatitis is listed as a serious, though uncommon, adverse event in the Wegovy FDA prescribing information. It has been observed in patients treated with GLP-1 receptor agonists, and Wegovy is no exception.
A 2024 updated meta-analysis published in Endocrinologia, Diabetes y Nutricion (Masson et al.) analysed semaglutide across multiple dose regimens and found no statistically significant increase in acute pancreatitis risk compared to placebo (odds ratio: 0.7, 95% CI: 0.5 to 1.2).
In the STEP weight-loss trial specifically, pancreatitis occurred in 3 of 1,306 participants taking semaglutide versus none in the placebo group.
A case report in PMC (2024) documented acute pancreatitis in a patient who had sourced semaglutide without medical supervision, underscoring the importance of physician-supervised use.
The complicating factor: obesity itself is an independent risk factor for pancreatitis, making it methodologically difficult to isolate the drug’s contribution in observational studies.
Warning signs of pancreatitis to act on immediately
- Sudden, severe pain in the upper abdomen, particularly if it radiates to the back.
- Persistent nausea or vomiting that does not resolve with the usual adjustment period.
- Fever, rapid heartbeat, or abdominal tenderness.
If any of these occur, stop Wegovy and seek same-day medical evaluation. Do not wait for a scheduled appointment.
If you have a personal history of pancreatitis or pancreatic disease, discuss this explicitly with your doctor before starting Wegovy.
6. Does Wegovy Cause Muscle Loss? What the Research on Lean Mass Actually Says
This is one of the more clinically important concerns about Wegovy, and the evidence deserves careful reading.
A 2024 systematic review in Expert Opinion on Pharmacotherapy examined semaglutide’s effect on lean mass across clinical trials.
The conclusion: semaglutide produces weight loss primarily through fat mass reduction, but notable reductions in lean mass were also observed, particularly in larger trials.
The SEMALEAN study (PMC 2025), a prospective real-world cohort of 106 patients with obesity treated with semaglutide 2.4 mg, found that mean weight loss of 13% at 12 months included a measurable reduction in lean mass alongside fat mass loss.
The study highlighted that assessing lean mass changes is critical to evaluating the quality of weight loss, not just the quantity.
What you can do to protect muscle while on Wegovy
- Resistance training (weight training, bodyweight exercises) is the most evidence-supported intervention for preserving lean mass during caloric restriction. Aim for at least two sessions per week.
- Ensure adequate dietary protein: at least 1.2 g to 1.6 g of protein per kg of body weight per day during active weight loss.
- Consider a DEXA scan or bioelectrical impedance assessment before and during treatment if lean mass preservation is a priority. This gives you an objective baseline.
- Do not reduce calories beyond what your doctor recommends. The combination of very low calorie intake and semaglutide-driven appetite suppression can accelerate lean tissue loss.
7. Who Should Not Take Wegovy? Contraindications and Precautions Relevant to the Indian Context
Wegovy is a Schedule H prescription drug in India, meaning it requires a valid prescription from a registered medical practitioner.
That regulatory classification exists for good reason: it is a potent medication with specific populations who should not use it.
Wegovy Contraindications and Special Precautions
| Category | Detail | Clinical Basis |
| Absolute Contraindication | Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 | FDA Boxed Warning, 2021-2026 |
| Absolute Contraindication | Prior serious allergic reaction to semaglutide or any Wegovy excipient | FDA Prescribing Info, Section 4 |
| Strong Precaution | History of pancreatitis or pancreatic disease | FDA Warnings, Section 5.2 |
| Strong Precaution | Pregnancy or planning to conceive (stop at least 2 months before) | FDA Prescribing Info, Section 8.1 |
| Strong Precaution | Personal history of diabetic retinopathy (type 2 diabetes) | FDA Warnings, Section 5.6 |
| Drug Interaction | Concurrent insulin or sulfonylureas: hypoglycaemia risk | Novo Nordisk HCP guidance |
| Drug Interaction | DPP-4 inhibitors (‘-gliptin’ drugs): should typically be stopped when starting a GLP-1 | Indian endocrinology prescribing guidance (PharmEasy clinical, 2025) |
| Not Recommended | Severe gastroparesis | FDA Prescribing Info, Section 5 |
| Planned Surgery | Inform anaesthesiologist: delayed gastric emptying increases aspiration risk under general anaesthesia | FDA postmarketing update |
Sources: FDA Wegovy Prescribing Information (2025) | PharmEasy Clinical Guidance (2025)
An important note for the Indian context: semaglutide is available in India primarily through Rybelsus (oral semaglutide for type 2 diabetes) and through specialist import pathways for Wegovy.
Always source through a registered pharmacist with a valid prescription. Self-medicating or accessing through unverified channels carries significant safety risks.
How Long Do Wegovy Side Effects Last?
Duration varies by side effect type and by the individual. The following overview reflects data from the STEP clinical trial programme and the FDA prescribing information.
| Side Effect | Typical Onset | Typical Duration | Self-Resolving? |
| Nausea / Vomiting | Days 2-5 after dose escalation | 4-8 weeks per step | Yes, for most |
| Diarrhea | First 1-4 weeks at new dose | Weeks | Yes |
| Fatigue | 48-72 hrs post-injection | Reduces with each dose cycle | Yes |
| Hair loss | 2-4 months after weight loss begins | Peaks then reverses as weight stabilises | Usually yes |
| Constipation | First 1-2 months | May persist longer than nausea | Yes |
| Injection site reactions | Immediately post-injection | Brief; rotate injection sites | Yes |
Sources: STEP-1 (Wilding et al., NEJM 2021) | STEP-5 (Garvey et al., Nature Medicine 2022) | FDA Prescribing Information 2025
Bottom Line
Wegovy’s most common side effects are gastrointestinal and, for most people, improve meaningfully within eight weeks, as confirmed by the STEP-1 trial (NEJM 2021).
Hair loss and fatigue are real but typically temporary, linked to the weight loss itself rather than direct drug toxicity.
Serious events like pancreatitis and the thyroid warning require awareness, not panic: the absolute risks are low in people without relevant contraindications.
If you are in India and exploring semaglutide-based options, work with an endocrinologist or bariatric physician who can assess your personal risk profile before prescribing.
Frequently Asked Questions About Wegovy Side Effects
What are the most common Wegovy side effects?
The most common Wegovy side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain.
These occur at rates significantly above placebo, particularly at the 2.4 mg maintenance dose, per the STEP-1 trial (NEJM 2021). They are most intense during dose escalation and generally improve within four to eight weeks.
Fatigue and headache are also commonly reported, per the FDA prescribing information.
Does Wegovy cause permanent hair loss?
In most cases, no. The hair loss associated with Wegovy is telogen effluvium, a temporary, diffuse shedding triggered by the physiological stress of rapid weight loss.
It typically peaks two to four months into treatment and reverses as weight stabilises. 3% of Wegovy trial participants reported alopecia versus 1% on placebo, per the FDA prescribing information. Persistent or severe hair loss should be evaluated by a dermatologist.
What is the thyroid cancer risk with Wegovy?
The FDA boxed warning is based on rodent studies. Large multinational human cohort studies published in BMJ (2024) and Thyroid (2025) have not confirmed a significant thyroid cancer risk in the general population.
Wegovy is contraindicated only in people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
How long do Wegovy side effects last?
Most gastrointestinal side effects peak in the days following a dose escalation and improve significantly within four to eight weeks at a stable dose, per the STEP-1 trial (NEJM 2021).
Hair shedding may begin two to four months after significant weight loss and typically reverses within six months of weight stabilisation.
The STEP-5 two-year trial (Nature Medicine 2022) found no new long-term risks emerging over time beyond those established in the first year.
Who should not take Wegovy in India?
Two absolute contraindications apply per the FDA prescribing information: a personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Wegovy should also not be used during pregnancy or while breastfeeding.
In India, Wegovy is a Schedule H prescription drug and should only be initiated under the supervision of a qualified endocrinologist or bariatric physician.
